Vaginal/Urinary Tract Health*

Jarrow Formulas’ Fem-Dophilus® contains two patented probiotic microorganisms, Lacticaseibacillus rhamnosus GR-1® and Limosilactobacillus reuteri RC-14®, that are clinically documented to promote vaginal health naturally.*

Product Benefits

Women seeking to maintain internal, especially vaginal, floral balance, may benefit from using Jarrow Formulas’ Fem-Dophilus®.* Healthy flora has been documented as a contributor to vaginal and urinary tract health.* 

Product Highlights

• -Patented Probiotic Microorganisms - (Lacticaseibacillus Rhamnosus GR-1® and Limosilactobacillus. Reuteri RC-14®) 
• -25+ Years of Research Support Its Benefits 
• -Studies Demonstrating Safety and Efficacy* 
• -Promotes Vaginal Health Naturally*
• -Suitable For Vegetarians/Vegans
• -Free Of Major Allergens
• -With Non-GMO Strains
• -Gluten Free

Active Ingredient(s)

Lacticaseibacillus . rhamnosus GR-1® and Limosilactobacillus reuteri RC-14® 

Promotes beneficial microorganisms that populate the vaginal tract while crowding out other bacteria and yeasts.* 

A Probiotic For Vaginal Health

Jarrow Formulas’ Fem-Dophilus® contains two patented and clinically tested strains of probiotic bacteria, Lacticaseibacillus rhamnosus GR-1® and Limosilactobacillus reuteri RC-14®, discovered and developed by Drs. Gregor Reid and Andrew Bruce of Urex Biotech. Research has confirmed that GR-1 and RC-14 taken as an oral supplement colonize and support a healthy vaginal tract.* Over twenty-five years of research has shown that GR-1 and RC-14 help maintain the balance of flora important to vaginal and urinary tract health.* 

This patented product is manufactured at a Good Manufacturing Practices (GMP) facility under strict quality control to ensure potency and consistency. The probiotic strains in Jarrow  Formulas’ Fem-Dophilus® are delivered in a proprietary polysaccharide matrix that protects the bacteria from stomach acid and enhances the survival of these species as they reach the intestinal tract.* 

25+ Years of Research & Clinical Studies

Since their initial discovery, GR-1  (originally isolated in 1980 from the distal urethra of a healthy woman), and RC-14  (originally isolated in 1985 from the vagina of a healthy woman) have become well documented probiotic strains for women’s health. GR-1  and RC-14  were selected for their ability to populate the vaginal tract and crowd out other bacteria and yeasts, as well as confer benefits to the intestine and urinary tract.* 

After early scientific research established the benefits of both GR-1  and RC-14 , both strains were combined for scientific and clinical research beginning in 1988. Following 13 years of research, the first clinical study of the combination of both GR-1 and RC-14  was published in 2001 in the FEMS Immunology & Medical Microbiology. There are several published clinical studies on the combination of both GR-1  and RC-14  strains. 

Oral Probiotics Influence Vaginal Floral Balance

Clinical trials have found that oral intake of probiotics can significantly and beneficially affect the balance of vaginal flora.* However, only certain probiotics can provide this benefit. 

The major criteria required in selecting beneficial probiotics are their ability to colonize the vagina and reduce other vaginal microflora. In one trial, GR-1 and RC-14 administered in skim milk were given orally to 10 women twice daily for 14 days. GR-1 and RC-14  were recovered from the vagina and identified by morphology and molecular typing within 1 week of commencement of the trial. In another randomized clinical trial, 75% of women in the GR-1/RC-14 group obtained a normal vaginal flora composition while only 34% of women in the nonprobiotic group had normal vaginal flora. 

In order for a probiotic to be effective, significant numbers of live bacteria (indicated as Colony Forming Units or CFU) must survive when the probiotic is taken by mouth. Tests for the gastrointestinal survivability of strains have shown good results. GR-1 and RC-14 are also bile tolerant and survive passage through the gastrointestinal tract. RC-14 and GR-14 are tolerant to 0.3 and 0.5 percent (w/v) bile, respectively. According to the experts, both strains can therefore be considered both acid and bile tolerant given that a concentration of 0.3 percent is considered physiologically relevant.* 

The Fem-Dophilus® Difference

Several human and in vitro studies have documented the safety of GR-1 and RC-14. Jarrow Formulas obtains the materials for Fem-Dophilus® probiotics from a pharmaceutical GMP level manufacturer. Advanced and accurate genetic analyses are conducted to ensure the correct identity of the strains. This is in keeping with ultimate quality control. 

The strains in Fem-Dophilus® are well documented. Lacticaseibacillus rhamnosus (GR-1 ) and Limosilactobacillus reuteri (RC14) the patented probiotic bacterial strains that make up Jarrow Formulas’ Fem-Dophilus®, have been demonstrated in clinical studies to reach the vaginal tract and help address specific women’s health needs.*